Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Strides Pharma Science Limited
STARStrides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India. Address: Strides House, Bengaluru, India, 560076
Analytics
Zielpreis von Wall Street
158 475.75 INRKGV
80Dividendenrendite
0.18 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen STAR
Dividenden-Analyse STAR
Dividendenwachstum über 5 Jahre
-25 %Kontinuierliches Wachstum
1 JahrAusschüttungsquote 5-Jahres-Durchschnitt
23 %Verlauf der Dividende STAR
Bewertung der Aktie STAR
Finanzen STAR
Ergebnisse | 2019 | Dynamik |